Median Technologies announced that the Company has been selected as preferred vendor by a Top 3 pharmaceutical company, adding another one of the largest global pharmaceutical companies to its client portfolio. Median Technologies is now preferred provider for two of the Top 3 pharma companies, based on oncology sales. The Master Service Agreement (MSA) came after an in-depth selection process.

The new client has one of the largest oncology pipelines in the world and presents one of the highest R&D to revenue ratios in the pharmaceutical industry3. Median will manage central image reads for late phase clinical trials in the client?s oncology pipeline. The MSA is a recognition of Median?s performance, quality, and competitiveness for imaging services worldwide.